DK1326630T3 - Anvendelse af GLP-2-peptider - Google Patents

Anvendelse af GLP-2-peptider

Info

Publication number: DK1326630T3
Authority: DK; Denmark
Prior art keywords: glp; peptides; hyperparathyroidism; glucagon; analogues
Prior art date: 2000-09-18

Application number

DK01982302T

Other languages

English (en)

Inventor

Dennis Bang Henriksen

Jens Juul Holst

Original Assignee

Sanos Bioscience As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-18

Filing date

2001-09-17

Publication date

2008-09-15

2000-09-18 Priority claimed from GB0022844A external-priority patent/GB0022844D0/en

2000-12-07 Priority claimed from GB0029920A external-priority patent/GB0029920D0/en

2001-09-17 Application filed by Sanos Bioscience As filed Critical Sanos Bioscience As

2008-09-15 Application granted granted Critical

2008-09-15 Publication of DK1326630T3 publication Critical patent/DK1326630T3/da

Links

101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract 2
102400000326 Glucagon-like peptide 2 Human genes 0.000 title 1
201000002980 Hyperparathyroidism Diseases 0.000 abstract 1
102100040918 Pro-glucagon Human genes 0.000 abstract 1
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Zoology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Child & Adolescent Psychology (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK01982302T 2000-09-18 2001-09-17 Anvendelse af GLP-2-peptider DK1326630T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0022844A GB0022844D0 (en)	2000-09-18	2000-09-18	Use of GLP-1 and GLP-2 peptides
GB0029920A GB0029920D0 (en)	2000-12-07	2000-12-07	Use of glp-1 and glp-2 peptides
PCT/EP2001/010714 WO2002022151A2 (en)	2000-09-18	2001-09-17	Use of glp-1 and flp-2 peptides for treatment of bone disorders

Publications (1)

Publication Number	Publication Date
DK1326630T3 true DK1326630T3 (da)	2008-09-15

Family

ID=26245018

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK01982302T DK1326630T3 (da)	2000-09-18	2001-09-17	Anvendelse af GLP-2-peptider
DK01967517.2T DK1414486T3 (da)	2000-09-18	2001-09-18	Anvendelse af GLP-2 i kombination med et andet terapeutisk middel ved knoglerelaterede sygdomme

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK01967517.2T DK1414486T3 (da)	2000-09-18	2001-09-18	Anvendelse af GLP-2 i kombination med et andet terapeutisk middel ved knoglerelaterede sygdomme

Country Status (11)

Country	Link
US (2)	US6770620B2 (da)
EP (3)	EP1326630B1 (da)
JP (2)	JP5161412B2 (da)
AT (2)	ATE396738T1 (da)
AU (2)	AU2002213925A1 (da)
CY (2)	CY1108263T1 (da)
DE (2)	DE60134251D1 (da)
DK (2)	DK1326630T3 (da)
ES (2)	ES2310192T3 (da)
PT (2)	PT1326630E (da)
WO (2)	WO2002022151A2 (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070135345A1 (en) *	2000-09-18	2007-06-14	Henriksen Dennis B	Use of GLP-2 for the treatment or prevention, of bone-related disorders
US7371721B2 (en) *	2000-09-18	2008-05-13	Sanos Bioscience A/S	Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) *	2000-09-18	2007-03-06	Sanos Bioscience A/S	Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20080249016A1 (en) *	2000-09-18	2008-10-09	Sanos Bioscience A/S	Use of GLP-2 in a combination treatment for bone-related disorders
DE60134251D1 (de) *	2000-09-18	2008-07-10	Sanos Bioscience As	Verwendung von glp-2-peptiden
RO120121B1 (ro) *	2000-12-18	2005-09-30	Elena Ionaşcu	Soluţie injectabilă, cu efect antiinflamator, procedeu de obţinere şi metodă de tratament a bolilor autoimune
CA2372450A1 (en) *	2001-05-10	2001-09-19	Pharmaceutical Partners Of Canada Inc.	Liquid injectable formulation of disodium pamidronate
DE10135315A1 (de) *	2001-07-19	2003-01-30	Bayer Ag	Stents
ES2545090T3 (es)	2001-12-21	2015-09-08	Human Genome Sciences, Inc.	Proteínas de fusión de albúmina y GCSF
MXPA04011203A (es)	2002-05-17	2005-07-14	Univ Duke	Metodo para tratar la obesidad.
US20050215552A1 (en) *	2002-05-17	2005-09-29	Gadde Kishore M	Method for treating obesity
WO2004084859A2 (en)	2003-03-21	2004-10-07	Nastech Pharmaceutical Company Inc.	Nasal calcitonin formulations containing chlorobutanol
JP2007525425A (ja) *	2003-03-24	2007-09-06	ノボ　ノルディスク　アクティーゼルスカブ	Ｇｌｐ−２誘導体
EP1870096A3 (en) *	2003-04-29	2011-04-20	Orexigen Therapeutics, Inc.	Compositions for affecting weight loss
EP2316456B1 (en) *	2003-04-29	2017-06-14	Orexigen Therapeutics, Inc.	Compositions for affecting weight loss comprising an opioid antagonist and bupropion
ES2383752T3 (es)	2003-05-15	2012-06-26	Trustees Of Tufts College	Analogos estables de GLP-1
US7713959B2 (en) *	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
CA2553207A1 (en) *	2004-01-13	2005-08-04	Kishore M. Gadde	Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
JP2007536229A (ja) *	2004-05-03	2007-12-13	デューク・ユニバーシティー	体重減少に作用するための組成物
ATE498631T1 (de) *	2005-05-04	2011-03-15	Zealand Pharma As	Glucagon-like-peptide-2- (glp-2-) analoga
WO2006135660A2 (en) *	2005-06-10	2006-12-21	University Of Chicago	Therapies involving lymphotoxin beta receptor
WO2007067341A2 (en) *	2005-11-22	2007-06-14	Orexigen Therapeutics, Inc.	Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) *	2005-11-23	2007-08-09	Orexigen Therapeutics, Inc.	Compositions and methods for reducing food cravings
CA2651283A1 (en) *	2006-05-15	2007-11-22	Wisconsin Alumni Research Foundation	Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
US8916195B2 (en) *	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
US8642727B2 (en)	2006-11-08	2014-02-04	Zealand Pharma A/S	Selective glucagon-like-peptide-2 (GLP-2) analogues
KR101479324B1 (ko)	2006-11-09	2015-01-05	오렉시젠 세러퓨틱스 인크.	신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
MX343867B (es)	2006-11-09	2016-11-25	Orexigen Therapeutics Inc	Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
EP2124907B1 (en)	2007-03-19	2018-05-30	Vita Sciences, Llc	Transdermal patch and method for delivery of vitamin b12
US20100204116A1 (en) *	2007-09-11	2010-08-12	Dorian Bevec	Use of calcitonin as anti-angiogenic agent
CA2725930A1 (en) *	2008-05-30	2009-12-30	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
WO2010042145A1 (en) *	2008-09-19	2010-04-15	Nektar Therapeutics	Polymer conjugates of glp-2-like peptides
AU2009292643B2 (en)	2008-09-19	2016-02-18	Nektar Therapeutics	Polymer conjugates of therapeutic peptides
CA2740685C (en)	2008-10-17	2018-09-11	Sanofi-Aventis Deutschland Gmbh	Combination of an insulin and a glp-1 agonist
EP2480246A4 (en)	2009-09-23	2013-02-27	Biokier Inc	COMPOSITION AND METHOD FOR THE TREATMENT OF DIABETES
EP2311486A1 (en) *	2009-10-07	2011-04-20	Nestec S.A.	GLP-2 for use in intestine and muscle recovery
JP5973918B2 (ja)	2009-11-13	2016-08-23	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
AU2010317995B2 (en)	2009-11-13	2014-04-17	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
US9248123B2 (en)	2010-01-11	2016-02-02	Orexigen Therapeutics, Inc.	Methods of providing weight loss therapy in patients with major depression
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
JP6199186B2 (ja)	2010-08-30	2017-09-20	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CA2835147A1 (en) *	2011-05-24	2012-11-29	Polyvalor S.E.C.	Compositions and methods for efficacious and safe delivery of sirna using specific chitosan-based nanocomplexes
RU2650616C2 (ru)	2011-08-29	2018-04-16	Санофи-Авентис Дойчланд Гмбх	Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MX356958B (es)	2012-05-03	2018-06-20	Zealand Pharma As	Análogos de péptido-2 tipo glucagón (glp-2).
AU2013271622B2 (en)	2012-06-06	2018-03-01	Nalpropion Pharmaceuticals Llc	Methods of treating overweight and obesity
US10092513B2 (en)	2013-04-03	2018-10-09	Sanofi	Treatment of diabetes mellitus by long-acting formulations of insulins
US10493042B2 (en)	2013-08-01	2019-12-03	University-Industry Cooperation Group Of Kyung Hee University	Method for preventing or treating diabetes mellitus, and method for screening for diabetes mellitus therapeutic agent
WO2015016682A1 (ko) *	2013-08-01	2015-02-05	경희대학교 산학협력단	당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법
US8969371B1 (en)	2013-12-06	2015-03-03	Orexigen Therapeutics, Inc.	Compositions and methods for weight loss in at risk patient populations
HRP20230470T1 (hr)	2014-12-12	2023-07-21	Sanofi-Aventis Deutschland Gmbh	Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
WO2016205701A1 (en)	2015-06-19	2016-12-22	University Of Southern California	Enteral fast access tract platform system
CA2990230A1 (en)	2015-06-19	2016-12-22	University Of Southern California	Compositions and methods for modified nutrient delivery
WO2018009778A1 (en) *	2016-07-07	2018-01-11	Baylor College Of Medicine	Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes
US10774127B2 (en)	2016-10-12	2020-09-15	University Of Copenhagen	Peptide dual agonists of GIPR and GLP2R
CN117384274A (zh)	2016-12-09	2024-01-12	西兰制药公司	酰化的glp-1/glp-2双重激动剂
WO2019072963A1 (en)	2017-10-12	2019-04-18	University Of Copenhagen	POLYTHERAPY FOR THE TREATMENT OF BONE DISEASES
EP3699187A1 (en)	2019-02-21	2020-08-26	Universite D'angers	Peptide targeting gip and glp-2 receptors for treating bone disorders
US20210187077A1 (en) *	2019-12-23	2021-06-24	Idaho State University	GLP-1 Agonist Conjugates for Sustained Glycemic Control
KR20210082120A (ko) *	2019-12-24	2021-07-02	한미약품 주식회사	Glp-2 또는 이의 결합체를 포함하는 골 대사성 질환에 대한 예방 또는 치료용 약학적 조성물
KR20220041765A (ko) *	2020-09-25	2022-04-01	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 골 질환에 대한 예방 또는 치료용 약학적 조성물

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3750402T3 (de)	1986-05-05	1997-04-10	Gen Hospital Corp	Insulinotropes hormon.
ATE193541T1 (de)	1989-03-20	2000-06-15	Gen Hospital Corp	Insulinotropes hormon
CA2073856C (en)	1990-01-24	2002-12-03	Douglas I. Buckley	Glp-1 analogs useful for diabetes treatment
PT101031B (pt)	1991-11-05	2002-07-31	Transkaryotic Therapies Inc	Processo para o fornecimento de proteinas por terapia genetica
US5512459A (en)	1993-07-20	1996-04-30	Bionebraska, Inc.	Enzymatic method for modification or recombinant polypeptides
US5789379A (en)	1995-04-14	1998-08-04	Allelix Biopharmaceutical Inc.	Glucagon-like peptide-2 analogs
US5834428A (en)	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US5990077A (en)	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en)	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
US5912229A (en)	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
ATE505485T1 (de) *	1996-03-01	2011-04-15	Novo Nordisk As	Appetithemmendes peptid, zusammensetzung und verwendung
EP2218734B1 (en)	1996-04-12	2013-06-05	1149336 Ontario Inc.	Glucagon-like peptide-2 analogs
DK0909312T3 (da)	1996-07-05	2003-03-17	Novo Nordisk As	Fremgangsmåde til fremstilling af polypeptider
US5994500A (en)	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides
AU4112497A (en)	1996-08-30	1998-03-19	Novo Nordisk A/S	Glp-2 derivatives
US6011155A (en) *	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
AU5696298A (en)	1996-12-06	1998-06-29	Amgen, Inc.	Keratinocyte growth factors and uses thereof
US5952301A (en)	1996-12-10	1999-09-14	1149336 Ontario Inc.	Compositions and methods for enhancing intestinal function
DK0946591T3 (da)	1996-12-13	2007-08-13	Nps Allelix Corp	Klonede glucagon-lignende peptid-2 receptorer
US6077949A (en)	1996-12-13	2000-06-20	Allelix Biopharmaceuticals, Inc.	Cloned glucagon-like peptide 2 receptors
US6051557A (en)	1997-05-16	2000-04-18	1149336 Ontario Inc.	Methods of enhancing functioning of the upper gastrointestinal tract
AU746633B2 (en) *	1997-05-16	2002-05-02	1149336 Ontario Inc.	Methods of enhancing functioning of the upper gastrointestinal tract
AU8671798A (en)	1997-07-30	1999-02-22	Betagene, Inc.	Methods and compositions relating to no-mediated cytotoxicity
JP2001516765A (ja)	1997-09-12	2001-10-02	ヴォルフゲオルグフォースマン	真性糖尿病及び肥満の治療のための組成物
EP1049790A1 (en)	1998-01-23	2000-11-08	Novo Nordisk A/S	Process for making desired polypeptides in yeast
JP2002501889A (ja)	1998-02-02	2002-01-22	トラスティーズオブタフツカレッジ	グルコース代謝を調節する方法、およびそれに関連する試薬
JP2002504527A (ja)	1998-02-27	2002-02-12	ノボノルディスクアクティーゼルスカブ	部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
WO1999046283A1 (en)	1998-03-09	1999-09-16	Zealand Pharmaceuticals A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
FR2777283B1 (fr) *	1998-04-10	2000-11-24	Adir	Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1999058144A1 (en)	1998-05-11	1999-11-18	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
AU5480199A (en)	1998-08-21	2000-03-14	Point Therapeutics, Inc.	Regulation of substrate activity
US6193997B1 (en)	1998-09-27	2001-02-27	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using membrane mimetics
EP1119625B1 (en)	1998-10-07	2005-06-29	Medical College Of Georgia Research Institute, Inc.	Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6416737B1 (en) *	1998-11-19	2002-07-09	Board Of Trustees Of The University Of Arkansas	Increasing bone strength with selected bisphosphonates
CZ295891B6 (cs) *	1998-12-07	2005-11-16	Societe De Conseils De Recherches Et D'application	Analogy GLP-1, substituované na pozici 35, jejich použití a farmaceutické prostředky je obsahující
CZ303399B6 (cs) *	1998-12-07	2012-08-29	Ipsen Pharma S.A.S.	Peptidový analog GLP-1 a farmaceutický prostredek jej obsahující
CO5150173A1 (es)	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6271200B1 (en)	1998-12-21	2001-08-07	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
WO2000042026A1 (en)	1999-01-15	2000-07-20	Novo Nordisk A/S	Non-peptide glp-1 agonists
GB9905416D0 (en)	1999-03-09	1999-05-05	Allelix Biopharma	Small molecules having GLP-2 like activity
US6110949A (en) *	1999-06-24	2000-08-29	Novartis Ag	N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
WO2001041779A2 (en)	1999-12-08	2001-06-14	1149336 Ontario Inc.	Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
WO2001087322A2 (en) *	2000-05-17	2001-11-22	Bionebraska, Inc.	Peptide pharmaceutical formulations
EP1294757B1 (en) *	2000-06-16	2006-11-22	Eli Lilly And Company	Glucagon-like peptide-1 analogs
WO2002010195A2 (en) *	2000-08-02	2002-02-07	Theratechnologies Inc.	Modified peptides with increased potency
DE60134251D1 (de) *	2000-09-18	2008-07-10	Sanos Bioscience As	Verwendung von glp-2-peptiden
WO2002066062A2 (en) *	2001-02-01	2002-08-29	Drucker Daniel J	Enhancement of glp-2 activity

2001
- 2001-09-17 DE DE60134251T patent/DE60134251D1/de not_active Expired - Lifetime
- 2001-09-17 AU AU2002213925A patent/AU2002213925A1/en not_active Abandoned
- 2001-09-17 ES ES01982302T patent/ES2310192T3/es not_active Expired - Lifetime
- 2001-09-17 DK DK01982302T patent/DK1326630T3/da active
- 2001-09-17 EP EP01982302A patent/EP1326630B1/en not_active Expired - Lifetime
- 2001-09-17 EP EP08156283A patent/EP1970072A1/en not_active Withdrawn
- 2001-09-17 US US09/954,304 patent/US6770620B2/en not_active Expired - Fee Related
- 2001-09-17 WO PCT/EP2001/010714 patent/WO2002022151A2/en active IP Right Grant
- 2001-09-17 AT AT01982302T patent/ATE396738T1/de active
- 2001-09-17 PT PT01982302T patent/PT1326630E/pt unknown
- 2001-09-17 JP JP2002526401A patent/JP5161412B2/ja not_active Expired - Fee Related
- 2001-09-18 AU AU2001287892A patent/AU2001287892A1/en not_active Abandoned
- 2001-09-18 EP EP01967517A patent/EP1414486B1/en not_active Expired - Lifetime
- 2001-09-18 PT PT01967517T patent/PT1414486E/pt unknown
- 2001-09-18 AT AT01967517T patent/ATE466592T1/de active
- 2001-09-18 JP JP2002528284A patent/JP5189723B2/ja not_active Expired - Fee Related
- 2001-09-18 DE DE60142084T patent/DE60142084D1/de not_active Expired - Lifetime
- 2001-09-18 WO PCT/GB2001/004178 patent/WO2002024214A2/en active Application Filing
- 2001-09-18 DK DK01967517.2T patent/DK1414486T3/da active
- 2001-09-18 ES ES01967517T patent/ES2345874T3/es not_active Expired - Lifetime
2003
- 2003-03-18 US US10/391,460 patent/US6943151B2/en not_active Expired - Fee Related
2008
- 2008-08-13 CY CY20081100866T patent/CY1108263T1/el unknown
2010
- 2010-07-30 CY CY20101100721T patent/CY1110721T1/el unknown

Also Published As

Publication number	Publication date
ES2310192T3 (es)	2009-01-01
PT1326630E (pt)	2008-09-02
JP2004508410A (ja)	2004-03-18
CY1108263T1 (el)	2014-02-12
DK1414486T3 (da)	2010-08-30
EP1414486B1 (en)	2010-05-05
EP1326630B1 (en)	2008-05-28
PT1414486E (pt)	2010-07-21
WO2002024214A3 (en)	2004-02-19
ATE466592T1 (de)	2010-05-15
US20040082507A1 (en)	2004-04-29
WO2002022151A2 (en)	2002-03-21
US20020037836A1 (en)	2002-03-28
WO2002024214A2 (en)	2002-03-28
EP1414486A2 (en)	2004-05-06
ES2345874T3 (es)	2010-10-05
DE60142084D1 (de)	2010-06-17
AU2002213925A1 (en)	2002-03-26
EP1970072A1 (en)	2008-09-17
CY1110721T1 (el)	2015-06-10
AU2001287892A1 (en)	2002-04-02
US6770620B2 (en)	2004-08-03
JP2004524268A (ja)	2004-08-12
JP5161412B2 (ja)	2013-03-13
ATE396738T1 (de)	2008-06-15
EP1326630A2 (en)	2003-07-16
WO2002022151A3 (en)	2003-03-13
DE60134251D1 (de)	2008-07-10
JP5189723B2 (ja)	2013-04-24
US6943151B2 (en)	2005-09-13

Publication	Publication Date	Title
DK1326630T3 (da)	2008-09-15	Anvendelse af GLP-2-peptider
EA200300026A1 (ru)	2003-04-24	Аналоги глюкагоноподобного пептида-1
CY1112687T1 (el)	2016-02-10	Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
TR200202194T2 (tr)	2003-01-21	Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
BR0214972B1 (pt)	2012-08-21	artigo absorvente.
DK1282611T3 (da)	2005-02-14	Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer
DE60121988D1 (de)	2006-09-14	Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
DE60127876D1 (de)	2007-05-24	Steuerbare Schlaufenstruktur
DK1349856T3 (da)	2005-10-17	Isoindolin-1-on-glucokinase-aktivatorer
BR0100865B1 (pt)	2013-01-08	artigo absorvente.
BR0103836B1 (pt)	2008-11-18	artigo absorvente.
BR0100961B1 (pt)	2010-06-15	artigo absorvente.
SE9904377D0 (sv)	1999-12-01	Pharmaceutical combinations
AU2003251529A8 (en)	2004-02-09	Planetarium and point light source for the use in same
MXPA03001826A (es)	2003-06-04	Derivados de arilpiperazina.
DE60217991D1 (de)	2007-03-22	Mit Wasser entfärbbarer bedruckter Artikel sowie mit Wasser entfärbbares Spielzeug mit demselben
CY1106200T1 (el)	2011-06-08	Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους
BR0212092B1 (pt)	2012-05-15	artigo absorvente.
ES1045661Y (es)	2001-03-16	Vela o fuente calorifera.
ES1046482Y (es)	2001-06-01	Mesa transportable perfeccionada.
ES1048822Y (es)	2002-02-16	Mesa plegable perfeccionada.
ES1046650Y (es)	2001-06-16	Cartel luminoso perfeccionado.
ES1045547Y (es)	2001-03-16	Botellero perfeccionado.
ES1046636Y (es)	2001-06-01	Cinturones ortopedicos hinchables.
ES1043962Y (es)	2000-08-01	Pata oscilante para somieres y similares.